 | |
| Clinical data | |
|---|---|
| Other names | XP21279 |
| Routes of administration | Oral[1][2][3] |
| Drug class | Dopamine precursor;Dopamine receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H21NO6 |
| Molar mass | 359.378 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
XP-21279 is asustained-releaselevodopa (L-DOPA)prodrug and hence adopamine precursor andnon-selectivedopamine receptor agonist which was under development for the treatment ofParkinson's disease.[4][1][3] It is takenby mouth.[1][2][3]
The drug is said to add a five-carbonesterconjugate to levodopa that allows it to beactively transported by high-capacitynutrienttransporters throughout the entiregastrointestinal tract.[2][3][5] Subsequently, it is rapidly converted into levodopa bycarboxylesterases.[2][3][5] Levodopa itself can only be transported by a short section of thesmall intestine and hence XP-21279 allows more time for levodopa to beabsorbed, in turn resulting in an increasedduration and possibly reduced fluctuations in dopamine levels between levodopa doses.[1][2][3]
As of June 2015, XP-21279 was inphase 2clinical trials.[4] As of May 2022, there have been no further developmental updates.[4] It was reported in 2018 that development of the drug had been discontinued several years prior.[6] A 2019 review reported that results were conflicting in phase 2 trials and that this likely resulted in the discontinuation of the drug's development.[5]
Many sources do not report thechemical structure of XP-21279, suggesting that its exact structure has not been disclosed.[7][8][9][6][10] However, one source appears to report its chemical structure.[11]